ATE120860T1 - Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten. - Google Patents

Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.

Info

Publication number
ATE120860T1
ATE120860T1 AT91903946T AT91903946T ATE120860T1 AT E120860 T1 ATE120860 T1 AT E120860T1 AT 91903946 T AT91903946 T AT 91903946T AT 91903946 T AT91903946 T AT 91903946T AT E120860 T1 ATE120860 T1 AT E120860T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
malignant tumors
activated oncogenes
malignancy
Prior art date
Application number
AT91903946T
Other languages
English (en)
Inventor
Martin A Cheever
David J Peace
Original Assignee
Washington Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington Res Found filed Critical Washington Res Found
Application granted granted Critical
Publication of ATE120860T1 publication Critical patent/ATE120860T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
AT91903946T 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten. ATE120860T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47064590A 1990-01-26 1990-01-26

Publications (1)

Publication Number Publication Date
ATE120860T1 true ATE120860T1 (de) 1995-04-15

Family

ID=23868429

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94109426T ATE180276T1 (de) 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten
AT91903946T ATE120860T1 (de) 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94109426T ATE180276T1 (de) 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten

Country Status (10)

Country Link
US (5) US5320947A (de)
EP (2) EP0513161B1 (de)
JP (3) JP2552047B2 (de)
AT (2) ATE180276T1 (de)
AU (1) AU639311B2 (de)
CA (1) CA2074720C (de)
DE (2) DE69108716T2 (de)
DK (1) DK0617124T3 (de)
ES (2) ES2134294T3 (de)
WO (1) WO1991011719A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011099A1 (en) * 1989-04-19 1990-10-19 Stephen C. Wardlaw Determination of lymphocyte reactivity to specific antigens in blood
ATE180276T1 (de) * 1990-01-26 1999-06-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
DE69228824T2 (de) * 1991-09-16 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville NACHWEISMETHODEN FÜR C-Raf-1-GENES.5
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US6953573B1 (en) * 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
WO1998021585A1 (en) 1996-11-15 1998-05-22 Cornell Research Foundation, Inc. Activated ras interaction assay
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6551780B1 (en) * 2000-03-31 2003-04-22 The Regents Of University Of California Detection of gene mutations or amplifications in melanocytic neoplasms
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
DK1905457T3 (da) * 1999-12-22 2012-05-29 Scripps Research Inst Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
GB0007088D0 (en) * 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
US6772026B2 (en) 2000-04-05 2004-08-03 Therics, Inc. System and method for rapidly customizing design, manufacture and/or selection of biomedical devices
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US20040076978A1 (en) * 2001-11-14 2004-04-22 Catherine Verfaillie Method to identify genes associated with chronic myelogenous leukemia
JP4758342B2 (ja) * 2003-06-03 2011-08-24 キャンティマー インコーポレイテッド 相変化センサー
WO2006086777A2 (en) 2005-02-11 2006-08-17 Memorial Sloan Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
EP1912680B1 (de) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2-peptide
JP5554925B2 (ja) * 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
US8171270B2 (en) * 2006-12-29 2012-05-01 Intel Corporation Asynchronous control transfer
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP3630131B1 (de) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University Verfahren zur erzeugung personalisierter krebsimpfstoffe für hunde
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411990A (en) * 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4643968A (en) * 1981-01-29 1987-02-17 Massachusetts Institute Of Technology Process for determining metabolism and growth of cells under various conditions
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
JPS62103573A (ja) * 1985-08-21 1987-05-14 オンコジ−ン・サイエンス・インコ−ポレ−テツド Ｒａｓがコ−ドしているタンパク質の検出用イムノアツセイ
JPH076982B2 (ja) * 1985-11-06 1995-01-30 株式会社ニチレイ 抗 体
WO1987006940A1 (en) * 1986-05-06 1987-11-19 The Regents Of The University Of California ASSAYS AND ANTIBODIES FOR N-myc PROTEINS
US4820631A (en) * 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
ATE180276T1 (de) * 1990-01-26 1999-06-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten

Also Published As

Publication number Publication date
US20040235070A1 (en) 2004-11-25
CA2074720A1 (en) 1991-07-27
JPH08275774A (ja) 1996-10-22
DE69108716D1 (de) 1995-05-11
EP0617124B1 (de) 1999-05-19
DE69131255T2 (de) 1999-12-16
DK0617124T3 (da) 1999-12-06
AU7329991A (en) 1991-08-21
JPH1169976A (ja) 1999-03-16
EP0513161A1 (de) 1992-11-19
US20030083229A1 (en) 2003-05-01
DE69131255D1 (de) 1999-06-24
US5773230A (en) 1998-06-30
CA2074720C (en) 2002-07-23
JPH05503996A (ja) 1993-06-24
AU639311B2 (en) 1993-07-22
EP0513161B1 (de) 1995-04-05
EP0617124A1 (de) 1994-09-28
US5601989A (en) 1997-02-11
ES2070492T3 (es) 1995-06-01
DE69108716T2 (de) 1995-08-17
US5320947A (en) 1994-06-14
JP2552047B2 (ja) 1996-11-06
ATE180276T1 (de) 1999-06-15
WO1991011719A1 (en) 1991-08-08
ES2134294T3 (es) 1999-10-01

Similar Documents

Publication Publication Date Title
ATE180276T1 (de) Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ATE535254T1 (de) Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
DE3784693D1 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
ATE125626T1 (de) Cytokeratin-tumormarkierer und test zu deren nachweis.
Walker Ulex europeus I—peroxidase as a marker of vascular endothelium: its application in routine histopathology
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
EP0362278A4 (de) Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs.
ATE156517T1 (de) Antisens-oligonukleotide zur behandlung von krebs
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE3888378D1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
ATE974T1 (de) Mittel und verfahren zur behandlung und verbesserung des aussehens von textilien.
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
BG93995A (bg) Хелати и комплекси на антибиотици с бивалентни и/или тривалентни метали, метод за получаването им и използването им за получаване на противоязвени средства
ATE178357T1 (de) Nachweismethoden für c-raf-1-genes.5
Harris et al. Detection of human leukaemia associated antigens in leukaemic serum and normal embryos
CH622922B (de) Verfahren zur herstellung von haertbaren kondensationsprodukten und deren verwendung als textilbehandlungsmittel.
DE58907851D1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69232554D1 (de) Einen Liganden enthaltendes Arzneimittel zur Behandlung und/oder Diagnose von Weichgeweben-Tumoren
DE69110034D1 (de) Methoden und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen.
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
NO901461L (no) Antistoffer mot retinoblastom-genprodukt og anvendelse derav.
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
Marando et al. Complex karyotype in a case of cutaneous lymphangiosarcoma associated with chronic lymphedema of the lower limb

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee